TNF and histiocytic sarcoma: Adalimumab (ADA; Humira® [AbbVie, North Chicago, IL, USA]) is a monoclonal antibody against tumor necrosis factor (TNF)‐α, and is the only medication approved in Japan (at a dose of 40 mg every week), the USA and the EU for the treatment of HS.13, 14, 15